Paving the Way With Innovative Research in Immuno-Oncology Bristol-Myers Squibb is leading the way through its extensive Immuno-Oncology (I-O) program across multiple tumor types. I-O is an innovative area of research that seeks to help the body's own immune system to fight cancer. Cancer is one of the leading causes of death worldwide, accounting for 1 in 8 deaths Estimated 2012 Worldwide Annual Diagnosis1 Brain: 256,000+ Head & neck: 686,000+ Lung Cancer (SCLC and NSCLC): 1.82 Million+ Melanoma: 232,000+ Breast: 1.67 Million+ Hodgkin Lymphoma: 65,000+ Pancreatic: 337,000+ Liver: 782,000+ Bladder: 429,000+ Multiple Myeloma: 114,000+ Non-Hodgkin Lymphoma: 385,000+ Gastric: 951,000+ Colorectal: 1.36 Million+ Renal Cell Carcinoma: 337,000+ The Different Types of Cancer Approaches Traditional cancer treatment approaches are directed towards cancer cells. ImmunoOncology ImmunoOncology is designed to work with your body's own immune system to help fight cancer. Chemotherapy Radiation Chemotherapy is the use of medicines that kill cancer cells. Radiation uses high-energy particles or waves to destroy cancer cells. Targeted therapy Surgery Surgery is an invasive procedure that is used to remove tumor tissue in an attempt to reduce cancer cells or improve symptoms in a patient. Targeted therapy uses drugs or other treatments to more precisely identify and attack cancer cells directly. Immuno-Oncology is different from other cancer treatments because it is designed to work with the body's own immune system to fight cancer Across In Immuno-Oncology, Bristol-Myers Squibb is Exploring: 6 20+ clinical targets tumor types The Immune System and Cancer Normally, the immune system recognizes cancer cells and initiates an anti-tumor response to eliminate cancer. However, cancer cells may evade the body’s protective immune response by exploiting key immune checkpoint pathways that are regulators of T-cell activity and can be used by the tumor as defense mechanisms against the immune system. Inactive Natural Killer Cell Activated T Cell Activated T Cell Activated Natural Killer Cell PD-1 T cell receptor MHC LAG-3 Tumor Cell PD-L1 or PD-L2 LAG-3 Tumor Cell Cancer Cell Adaptor protein CD137 PD-1 SLAMF7 SLAMF7 CD137L KIR Tumor Cell CTLA-4 CD-137 Activated T Cell CD-80 or CD86 Inactive T Cell Antigen-Presenting Cell CTLA-4 Antigen-Presenting Cell Bristol-Myers Squibb is exploring the potential of a number of immune system pathways: as well as additional Immuno-Oncology pathways that work with the innate immune system and tumor microenvironment For more information, please visit ImmunoOncologyNow.com © 2015 Bristol-Myers Squibb Company ONCUS15UB00393-01-01 05/15